Immune and targeted therapy for nasopharyngeal carcinoma
Nasopharyngeal carcinoma is closely related to Epstein-Barr virus(EBV)and is currently clinically treated with radiotherapy alone or concurrent radiotherapy.Although this approach is effective in patients who are sensitive to radiotherapy,the prognosis for patients with locally advanced or distant metastatic nasopharyngeal cancer remains poor.With the development of immunotherapy and molecular targeting therapy in recent years,peripatetic cell therapy,immune checkpoints and multi-molecular targets and pathways have gradually become hot spots in the clinical treatment of nasopharyngeal carcinoma.This paper reviews the immunotherapy and targeted therapy for nasopharyngeal carcinoma,with a view to provide a basis for the development of therapeutic tools and drugs for nasopharyngeal carcinoma.